A Double-Blind, Placebo-Controlled Trial to Assess Safety and Tolerability of (Thetanix) Bacteroides thetaiotaomicron in Adolescent Crohn's Disease
Thetanix (gastroresistant capsules containing lyophilized Bacteroides thetaiotaomicron) is a live biotherapeutic, under development for Crohn's disease, that antagonizes transcription factor nuclear factor kappa B, reducing proinflammatory cytokines, particularly tumor necrosis factor alpha. We...
Gespeichert in:
| Veröffentlicht in: | Clinical and translational gastroenterology 2020-12, Vol.12 (1), p.e00287-e00287 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e00287 |
|---|---|
| container_issue | 1 |
| container_start_page | e00287 |
| container_title | Clinical and translational gastroenterology |
| container_volume | 12 |
| creator | Hansen, Richard Sanderson, Ian R. Muhammed, Rafeeq Allen, Stephen Tzivinikos, Christos Henderson, Paul Gervais, Lisa Jeffery, Ian B. Mullins, David P. O'Herlihy, Eileen A. Weinberg, John D. Kitson, Geoff Russell, Richard K. Wilson, David C. |
| description | Thetanix (gastroresistant capsules containing lyophilized Bacteroides thetaiotaomicron) is a live biotherapeutic, under development for Crohn's disease, that antagonizes transcription factor nuclear factor kappa B, reducing proinflammatory cytokines, particularly tumor necrosis factor alpha. We aimed to assess safety and tolerability in adolescents with Crohn's disease in remission.
Subjects who were 16-18 years with Crohn's in remission (weighted pediatric Crohn's disease activity index 99% in part B. Two subjects reported adverse events deemed related-one in part A with eructation, flatulence, and reflux; one in part B with dizziness, abdominal pain, and headache. No serious adverse events were reported. There was no significant change in median calprotectin across part B (87.8 [4.4-447] to 50.5 [5.3-572], P = 0.44 by the Fisher exact test in the active group). No significant differences were found in microbiota profiles, but diversity seemed to increase in treated subjects.
Thetanix, after single and multiple doses, was well tolerated. Although the numbers in this study were small, the safety profile seems good. Future studies should explore efficacy. |
| doi_str_mv | 10.14309/ctg.0000000000000287 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7752678</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>33464732</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4563-d6dd16fe2dcd87e1fcaaa8731c7c9101ec6ee6dd38ecafe5fc040348318c97fb3</originalsourceid><addsrcrecordid>eNpdUdtO3DAQtRCoIMonFPmtVCJgx06cvFRall6QkIrUrdQ3y7EnxK3XRra3wHf0h-tlW7R0XjyaOed4Zg5Cbyg5o5yR_lzn2zOyHXUndtBBTZumYh3_vruV76OjlH6sQbzA-v4V2meMt1yw-gD9nuHLsBocVBfOenOKb5zSMIRqHnyOwTkweBGtcjgHPEsJUsJf1Qj5EStfWsFBVIN1thTCiE8WE2Tl7cM7fKF0hhisgYTzumpDVmFpdQweW49npnCTBp_xPIbJv0340iZQCV6jvVG5BEd_30P07eOHxfxzdf3l09V8dl1p3rSsMq0xtB2hNtp0AuiolVKdYFQL3VNCQbcABcM60GXiZtTlAIx3jHa6F-PADtH7je7daliCWY8SlZN30S5VfJRBWfmy4-0kb8MvKURTt6IrAs1GoOyUUoTxmUuJfDJKFqPk_0YV3vH2x8-sf7YUAN8A7oMrR0w_3eoeopxAuTxJQkVNSM-rmtRlzyJarZUZ-wOmt6Ma</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A Double-Blind, Placebo-Controlled Trial to Assess Safety and Tolerability of (Thetanix) Bacteroides thetaiotaomicron in Adolescent Crohn's Disease</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Hansen, Richard ; Sanderson, Ian R. ; Muhammed, Rafeeq ; Allen, Stephen ; Tzivinikos, Christos ; Henderson, Paul ; Gervais, Lisa ; Jeffery, Ian B. ; Mullins, David P. ; O'Herlihy, Eileen A. ; Weinberg, John D. ; Kitson, Geoff ; Russell, Richard K. ; Wilson, David C.</creator><creatorcontrib>Hansen, Richard ; Sanderson, Ian R. ; Muhammed, Rafeeq ; Allen, Stephen ; Tzivinikos, Christos ; Henderson, Paul ; Gervais, Lisa ; Jeffery, Ian B. ; Mullins, David P. ; O'Herlihy, Eileen A. ; Weinberg, John D. ; Kitson, Geoff ; Russell, Richard K. ; Wilson, David C.</creatorcontrib><description>Thetanix (gastroresistant capsules containing lyophilized Bacteroides thetaiotaomicron) is a live biotherapeutic, under development for Crohn's disease, that antagonizes transcription factor nuclear factor kappa B, reducing proinflammatory cytokines, particularly tumor necrosis factor alpha. We aimed to assess safety and tolerability in adolescents with Crohn's disease in remission.
Subjects who were 16-18 years with Crohn's in remission (weighted pediatric Crohn's disease activity index <12.5) were recruited. Each active dose comprised ∼108.2±1.4 colony forming units of B. thetaiotaomicron (randomized 4:1 active:placebo). Part A was single dose. Part B involved 7.5 days twice daily dosing. Serial stools were analyzed for calprotectin, 16S rRNA sequencing, and B. thetaiotaomicron real-time polymerase chain reaction. Bloods were taken serially. Subjects reported adverse events and recorded temperature twice daily.
Fifteen subjects were treated-8 in part A (75% men, median 17.1 years) and 10 in part B, including 3 from part A (80% men, median 17.1 years); all 18 completed. Seventy percent took concurrent immunosuppression. Reported compliance was >99% in part B. Two subjects reported adverse events deemed related-one in part A with eructation, flatulence, and reflux; one in part B with dizziness, abdominal pain, and headache. No serious adverse events were reported. There was no significant change in median calprotectin across part B (87.8 [4.4-447] to 50.5 [5.3-572], P = 0.44 by the Fisher exact test in the active group). No significant differences were found in microbiota profiles, but diversity seemed to increase in treated subjects.
Thetanix, after single and multiple doses, was well tolerated. Although the numbers in this study were small, the safety profile seems good. Future studies should explore efficacy.</description><identifier>ISSN: 2155-384X</identifier><identifier>EISSN: 2155-384X</identifier><identifier>DOI: 10.14309/ctg.0000000000000287</identifier><identifier>PMID: 33464732</identifier><language>eng</language><publisher>United States: Wolters Kluwer</publisher><subject>Adolescent ; Bacteroides thetaiotaomicron ; Biological Therapy - adverse effects ; Biological Therapy - methods ; Crohn Disease - immunology ; Crohn Disease - therapy ; DNA, Bacterial - isolation & purification ; Double-Blind Method ; Female ; Follow-Up Studies ; Freeze Drying ; Gastrointestinal Microbiome - genetics ; Gastrointestinal Microbiome - immunology ; Humans ; Inflammatory Bowel Disease ; Male ; Placebos - administration & dosage ; Placebos - adverse effects ; Remission Induction - methods ; RNA, Ribosomal, 16S - genetics ; Treatment Outcome</subject><ispartof>Clinical and translational gastroenterology, 2020-12, Vol.12 (1), p.e00287-e00287</ispartof><rights>Wolters Kluwer</rights><rights>Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.</rights><rights>2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4563-d6dd16fe2dcd87e1fcaaa8731c7c9101ec6ee6dd38ecafe5fc040348318c97fb3</citedby><cites>FETCH-LOGICAL-c4563-d6dd16fe2dcd87e1fcaaa8731c7c9101ec6ee6dd38ecafe5fc040348318c97fb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752678/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752678/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33464732$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hansen, Richard</creatorcontrib><creatorcontrib>Sanderson, Ian R.</creatorcontrib><creatorcontrib>Muhammed, Rafeeq</creatorcontrib><creatorcontrib>Allen, Stephen</creatorcontrib><creatorcontrib>Tzivinikos, Christos</creatorcontrib><creatorcontrib>Henderson, Paul</creatorcontrib><creatorcontrib>Gervais, Lisa</creatorcontrib><creatorcontrib>Jeffery, Ian B.</creatorcontrib><creatorcontrib>Mullins, David P.</creatorcontrib><creatorcontrib>O'Herlihy, Eileen A.</creatorcontrib><creatorcontrib>Weinberg, John D.</creatorcontrib><creatorcontrib>Kitson, Geoff</creatorcontrib><creatorcontrib>Russell, Richard K.</creatorcontrib><creatorcontrib>Wilson, David C.</creatorcontrib><title>A Double-Blind, Placebo-Controlled Trial to Assess Safety and Tolerability of (Thetanix) Bacteroides thetaiotaomicron in Adolescent Crohn's Disease</title><title>Clinical and translational gastroenterology</title><addtitle>Clin Transl Gastroenterol</addtitle><description>Thetanix (gastroresistant capsules containing lyophilized Bacteroides thetaiotaomicron) is a live biotherapeutic, under development for Crohn's disease, that antagonizes transcription factor nuclear factor kappa B, reducing proinflammatory cytokines, particularly tumor necrosis factor alpha. We aimed to assess safety and tolerability in adolescents with Crohn's disease in remission.
Subjects who were 16-18 years with Crohn's in remission (weighted pediatric Crohn's disease activity index <12.5) were recruited. Each active dose comprised ∼108.2±1.4 colony forming units of B. thetaiotaomicron (randomized 4:1 active:placebo). Part A was single dose. Part B involved 7.5 days twice daily dosing. Serial stools were analyzed for calprotectin, 16S rRNA sequencing, and B. thetaiotaomicron real-time polymerase chain reaction. Bloods were taken serially. Subjects reported adverse events and recorded temperature twice daily.
Fifteen subjects were treated-8 in part A (75% men, median 17.1 years) and 10 in part B, including 3 from part A (80% men, median 17.1 years); all 18 completed. Seventy percent took concurrent immunosuppression. Reported compliance was >99% in part B. Two subjects reported adverse events deemed related-one in part A with eructation, flatulence, and reflux; one in part B with dizziness, abdominal pain, and headache. No serious adverse events were reported. There was no significant change in median calprotectin across part B (87.8 [4.4-447] to 50.5 [5.3-572], P = 0.44 by the Fisher exact test in the active group). No significant differences were found in microbiota profiles, but diversity seemed to increase in treated subjects.
Thetanix, after single and multiple doses, was well tolerated. Although the numbers in this study were small, the safety profile seems good. Future studies should explore efficacy.</description><subject>Adolescent</subject><subject>Bacteroides thetaiotaomicron</subject><subject>Biological Therapy - adverse effects</subject><subject>Biological Therapy - methods</subject><subject>Crohn Disease - immunology</subject><subject>Crohn Disease - therapy</subject><subject>DNA, Bacterial - isolation & purification</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Freeze Drying</subject><subject>Gastrointestinal Microbiome - genetics</subject><subject>Gastrointestinal Microbiome - immunology</subject><subject>Humans</subject><subject>Inflammatory Bowel Disease</subject><subject>Male</subject><subject>Placebos - administration & dosage</subject><subject>Placebos - adverse effects</subject><subject>Remission Induction - methods</subject><subject>RNA, Ribosomal, 16S - genetics</subject><subject>Treatment Outcome</subject><issn>2155-384X</issn><issn>2155-384X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdUdtO3DAQtRCoIMonFPmtVCJgx06cvFRall6QkIrUrdQ3y7EnxK3XRra3wHf0h-tlW7R0XjyaOed4Zg5Cbyg5o5yR_lzn2zOyHXUndtBBTZumYh3_vruV76OjlH6sQbzA-v4V2meMt1yw-gD9nuHLsBocVBfOenOKb5zSMIRqHnyOwTkweBGtcjgHPEsJUsJf1Qj5EStfWsFBVIN1thTCiE8WE2Tl7cM7fKF0hhisgYTzumpDVmFpdQweW49npnCTBp_xPIbJv0340iZQCV6jvVG5BEd_30P07eOHxfxzdf3l09V8dl1p3rSsMq0xtB2hNtp0AuiolVKdYFQL3VNCQbcABcM60GXiZtTlAIx3jHa6F-PADtH7je7daliCWY8SlZN30S5VfJRBWfmy4-0kb8MvKURTt6IrAs1GoOyUUoTxmUuJfDJKFqPk_0YV3vH2x8-sf7YUAN8A7oMrR0w_3eoeopxAuTxJQkVNSM-rmtRlzyJarZUZ-wOmt6Ma</recordid><startdate>20201218</startdate><enddate>20201218</enddate><creator>Hansen, Richard</creator><creator>Sanderson, Ian R.</creator><creator>Muhammed, Rafeeq</creator><creator>Allen, Stephen</creator><creator>Tzivinikos, Christos</creator><creator>Henderson, Paul</creator><creator>Gervais, Lisa</creator><creator>Jeffery, Ian B.</creator><creator>Mullins, David P.</creator><creator>O'Herlihy, Eileen A.</creator><creator>Weinberg, John D.</creator><creator>Kitson, Geoff</creator><creator>Russell, Richard K.</creator><creator>Wilson, David C.</creator><general>Wolters Kluwer</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20201218</creationdate><title>A Double-Blind, Placebo-Controlled Trial to Assess Safety and Tolerability of (Thetanix) Bacteroides thetaiotaomicron in Adolescent Crohn's Disease</title><author>Hansen, Richard ; Sanderson, Ian R. ; Muhammed, Rafeeq ; Allen, Stephen ; Tzivinikos, Christos ; Henderson, Paul ; Gervais, Lisa ; Jeffery, Ian B. ; Mullins, David P. ; O'Herlihy, Eileen A. ; Weinberg, John D. ; Kitson, Geoff ; Russell, Richard K. ; Wilson, David C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4563-d6dd16fe2dcd87e1fcaaa8731c7c9101ec6ee6dd38ecafe5fc040348318c97fb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Bacteroides thetaiotaomicron</topic><topic>Biological Therapy - adverse effects</topic><topic>Biological Therapy - methods</topic><topic>Crohn Disease - immunology</topic><topic>Crohn Disease - therapy</topic><topic>DNA, Bacterial - isolation & purification</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Freeze Drying</topic><topic>Gastrointestinal Microbiome - genetics</topic><topic>Gastrointestinal Microbiome - immunology</topic><topic>Humans</topic><topic>Inflammatory Bowel Disease</topic><topic>Male</topic><topic>Placebos - administration & dosage</topic><topic>Placebos - adverse effects</topic><topic>Remission Induction - methods</topic><topic>RNA, Ribosomal, 16S - genetics</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hansen, Richard</creatorcontrib><creatorcontrib>Sanderson, Ian R.</creatorcontrib><creatorcontrib>Muhammed, Rafeeq</creatorcontrib><creatorcontrib>Allen, Stephen</creatorcontrib><creatorcontrib>Tzivinikos, Christos</creatorcontrib><creatorcontrib>Henderson, Paul</creatorcontrib><creatorcontrib>Gervais, Lisa</creatorcontrib><creatorcontrib>Jeffery, Ian B.</creatorcontrib><creatorcontrib>Mullins, David P.</creatorcontrib><creatorcontrib>O'Herlihy, Eileen A.</creatorcontrib><creatorcontrib>Weinberg, John D.</creatorcontrib><creatorcontrib>Kitson, Geoff</creatorcontrib><creatorcontrib>Russell, Richard K.</creatorcontrib><creatorcontrib>Wilson, David C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical and translational gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hansen, Richard</au><au>Sanderson, Ian R.</au><au>Muhammed, Rafeeq</au><au>Allen, Stephen</au><au>Tzivinikos, Christos</au><au>Henderson, Paul</au><au>Gervais, Lisa</au><au>Jeffery, Ian B.</au><au>Mullins, David P.</au><au>O'Herlihy, Eileen A.</au><au>Weinberg, John D.</au><au>Kitson, Geoff</au><au>Russell, Richard K.</au><au>Wilson, David C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Double-Blind, Placebo-Controlled Trial to Assess Safety and Tolerability of (Thetanix) Bacteroides thetaiotaomicron in Adolescent Crohn's Disease</atitle><jtitle>Clinical and translational gastroenterology</jtitle><addtitle>Clin Transl Gastroenterol</addtitle><date>2020-12-18</date><risdate>2020</risdate><volume>12</volume><issue>1</issue><spage>e00287</spage><epage>e00287</epage><pages>e00287-e00287</pages><issn>2155-384X</issn><eissn>2155-384X</eissn><abstract>Thetanix (gastroresistant capsules containing lyophilized Bacteroides thetaiotaomicron) is a live biotherapeutic, under development for Crohn's disease, that antagonizes transcription factor nuclear factor kappa B, reducing proinflammatory cytokines, particularly tumor necrosis factor alpha. We aimed to assess safety and tolerability in adolescents with Crohn's disease in remission.
Subjects who were 16-18 years with Crohn's in remission (weighted pediatric Crohn's disease activity index <12.5) were recruited. Each active dose comprised ∼108.2±1.4 colony forming units of B. thetaiotaomicron (randomized 4:1 active:placebo). Part A was single dose. Part B involved 7.5 days twice daily dosing. Serial stools were analyzed for calprotectin, 16S rRNA sequencing, and B. thetaiotaomicron real-time polymerase chain reaction. Bloods were taken serially. Subjects reported adverse events and recorded temperature twice daily.
Fifteen subjects were treated-8 in part A (75% men, median 17.1 years) and 10 in part B, including 3 from part A (80% men, median 17.1 years); all 18 completed. Seventy percent took concurrent immunosuppression. Reported compliance was >99% in part B. Two subjects reported adverse events deemed related-one in part A with eructation, flatulence, and reflux; one in part B with dizziness, abdominal pain, and headache. No serious adverse events were reported. There was no significant change in median calprotectin across part B (87.8 [4.4-447] to 50.5 [5.3-572], P = 0.44 by the Fisher exact test in the active group). No significant differences were found in microbiota profiles, but diversity seemed to increase in treated subjects.
Thetanix, after single and multiple doses, was well tolerated. Although the numbers in this study were small, the safety profile seems good. Future studies should explore efficacy.</abstract><cop>United States</cop><pub>Wolters Kluwer</pub><pmid>33464732</pmid><doi>10.14309/ctg.0000000000000287</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2155-384X |
| ispartof | Clinical and translational gastroenterology, 2020-12, Vol.12 (1), p.e00287-e00287 |
| issn | 2155-384X 2155-384X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7752678 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adolescent Bacteroides thetaiotaomicron Biological Therapy - adverse effects Biological Therapy - methods Crohn Disease - immunology Crohn Disease - therapy DNA, Bacterial - isolation & purification Double-Blind Method Female Follow-Up Studies Freeze Drying Gastrointestinal Microbiome - genetics Gastrointestinal Microbiome - immunology Humans Inflammatory Bowel Disease Male Placebos - administration & dosage Placebos - adverse effects Remission Induction - methods RNA, Ribosomal, 16S - genetics Treatment Outcome |
| title | A Double-Blind, Placebo-Controlled Trial to Assess Safety and Tolerability of (Thetanix) Bacteroides thetaiotaomicron in Adolescent Crohn's Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T06%3A38%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Double-Blind,%20Placebo-Controlled%20Trial%20to%20Assess%20Safety%20and%20Tolerability%20of%20(Thetanix)%20Bacteroides%20thetaiotaomicron%20in%20Adolescent%20Crohn's%20Disease&rft.jtitle=Clinical%20and%20translational%20gastroenterology&rft.au=Hansen,%20Richard&rft.date=2020-12-18&rft.volume=12&rft.issue=1&rft.spage=e00287&rft.epage=e00287&rft.pages=e00287-e00287&rft.issn=2155-384X&rft.eissn=2155-384X&rft_id=info:doi/10.14309/ctg.0000000000000287&rft_dat=%3Cpubmed_cross%3E33464732%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33464732&rfr_iscdi=true |